By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company of over 875 employees focused on diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry.

Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has U.S. offices in Palo Alto, CA and Philadelphia, PA, and has offices in various other locations in Europe. The company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what they do to accomplish results by driving to achieve Jazz’s mission: to improve patients’ lives by identifying, developing and commercializing important specialty pharmaceutical products to address unmet patient needs, and operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence.

U.S. addresses:
3180 Porter Drive
Palo Alto, CA 94304

1818 Market Street
Philadelphia, PA 19103

Key Statistics

Ownership: Public

Web Site: Jazz Pharmaceuticals
Symbol: JAZZ


Company News
Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Acceptance For Filing With Priority Review Of NDA For Defibrotide For Hepatic Veno-Occlusive Disease 9/30/2015 6:42:56 AM
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results 8/6/2015 7:34:23 AM
Jazz Pharmaceuticals (JAZZ) To Report 2015 Second Quarter Financial Results On August 5, 2015 7/23/2015 10:49:18 AM
Jazz Pharmaceuticals (JAZZ) To Present At Cantor Fitzgerald Healthcare Conference On July 8 7/2/2015 7:45:55 AM
Jazz Pharmaceuticals (JAZZ) Release: Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic 6/9/2015 6:30:18 AM
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Clinical Development Program Evaluating JZP-110 As A Potential Treatment Of Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Or With Obstructive Sleep Apnea (OSA) 6/8/2015 7:18:13 AM
Jazz Pharmaceuticals (JAZZ) To Present Abstracts From Ongoing Evaluations Of Xyrem (Sodium Oxybate) At SLEEP 2015 6/4/2015 8:03:09 AM
Jazz Pharmaceuticals (JAZZ) Announces Participation In Two Investor Conferences 5/18/2015 10:52:02 AM
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals Provide JZP-386 Program Update 5/8/2015 10:19:39 AM
Jazz Pharmaceuticals (JAZZ) Announces First Quarter 2015 Financial Results 5/8/2015 7:30:56 AM